Viral Conjunctivitis - Pipeline Review, H2 2018

Viral Conjunctivitis - Pipeline Review, H2 2018


  • Products Id :- GMDHC10730IDB
  • |
  • Pages: 43
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Viral Conjunctivitis-Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Viral Conjunctivitis-Pipeline Review, H2 2018, provides an overview of the Viral Conjunctivitis (Ophthalmology) pipeline landscape.

Viral conjunctivitis, or pinkeye, is a common, self-limiting condition that is typically caused by adenovirus. Viral conjunctivitis is highly contagious, usually for 10-12 days from onset as long as the eyes are red. Symptoms include itchy eyes, tearing, redness, discharge and light sensitivity (with corneal involvement). Treatment includes lubricants, vasoconstrictors and antihistamines.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Viral Conjunctivitis-Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Viral Conjunctivitis (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Viral Conjunctivitis (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Viral Conjunctivitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Preclinical stages are 1, 1 and 6 respectively.

Viral Conjunctivitis (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Viral Conjunctivitis (Ophthalmology).

- The pipeline guide reviews pipeline therapeutics for Viral Conjunctivitis (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Viral Conjunctivitis (Ophthalmology) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Viral Conjunctivitis (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Viral Conjunctivitis (Ophthalmology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Viral Conjunctivitis (Ophthalmology).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Viral Conjunctivitis (Ophthalmology) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Viral Conjunctivitis-Overview

Viral Conjunctivitis-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Viral Conjunctivitis-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Viral Conjunctivitis-Companies Involved in Therapeutics Development

Adenovir Pharma AB

NanoViricides Inc

Panoptes Pharma GesmbH

Shire Plc

Starpharma Holdings Ltd

Viral Conjunctivitis-Drug Profiles

APD-209-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

APD-514-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

astodrimer-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EKCCide-I-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

INV-102-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PP-001-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ranpirnase-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SHP-640-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Viral Conjunctivitis-Dormant Projects

Viral Conjunctivitis-Discontinued Products

Viral Conjunctivitis-Product Development Milestones

Featured News & Press Releases

May 13, 2013: Starpharma's Dendrimer SPL7013 Demonstrates Potential As Viral Conjunctivitis Treatment

Oct 11, 2012: Adenovir Pharma Announces Completion Of Phase I Study Of APD -209 To Treat Epidemic Keratoconjunctivitis

Aug 22, 2011: Researchers Discover New Drug To Treat Epidemic Keratoconjuntivitis

May 05, 2010: Foresight Biotherapeutics, Inc 's Drug FST-100 Reduces Infectious Adenoviral Titers And Improves Clinical Signs in Conjunctivitis Model

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Figures

Number of Products under Development for Viral Conjunctivitis, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products by Targets, H2 2018

Number of Products by Stage and Targets, H2 2018

Number of Products by Mechanism of Actions, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018

List of Tables

Number of Products under Development for Viral Conjunctivitis, H2 2018

Number of Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Viral Conjunctivitis-Pipeline by Adenovir Pharma AB, H2 2018

Viral Conjunctivitis-Pipeline by NanoViricides Inc, H2 2018

Viral Conjunctivitis-Pipeline by Panoptes Pharma GesmbH, H2 2018

Viral Conjunctivitis-Pipeline by Shire Plc, H2 2018

Viral Conjunctivitis-Pipeline by Starpharma Holdings Ltd, H2 2018

Viral Conjunctivitis-Dormant Projects, H2 2018

Viral Conjunctivitis-Discontinued Products, H2 2018

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Adenovir Pharma AB

NanoViricides Inc

Panoptes Pharma GesmbH

Shire Plc

Starpharma Holdings Ltd

Viral Conjunctivitis Therapeutic Products under Development, Key Players in Viral Conjunctivitis Therapeutics, Viral Conjunctivitis Pipeline Overview, Viral Conjunctivitis Pipeline, Viral Conjunctivitis Pipeline Assessment

select a license
Single User License
USD 2000 INR 138340
Site License
USD 4000 INR 276680
Corporate User License
USD 6000 INR 415020

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com